產(chǎn)品名稱 |
NCI-H865 [H865] |
商品貨號(hào) |
B165375 |
Organism |
Homo sapiens, human |
Tissue |
lung |
Product Format |
frozen |
Culture Properties |
suspension, Cultures grow as floating aggregates of round cell clusters. |
Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Disease |
stage L,carcinoma; classic small cell lung cancer |
Age |
54 years |
Gender |
female |
Ethnicity |
Caucasian |
Applications |
The line was established in November 1984. |
Derivation |
The line was established in November 1984. |
Clinical Data |
The patient received prior chemotherapy and radiation therapy. The patient was a smoker. female Caucasian 54 years |
Comments |
The line was established in November 1984. The patient received prior chemotherapy and radiation therapy. The patient was a smoker. 40. |
Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
Subculturing |
Medium Renewal: Add fresh medium every 3 to 4 days (depending on cell density) Cultures can be maintained by addition of fresh medium. |
Cryopreservation |
Culture medium, 95%; DMSO, 5% |
Culture Conditions |
Temperature: 37.0°C |
STR Profile |
Amelogenin: X CSF1PO: 14 D13S317: 8 D16S539: 9 D5S818: 12 D7S820: 10 THO1: 9.3 TPOX: 8 vWA: 17 |
Name of Depositor |
AF Gazdar, JD Minna |
Deposited As |
Homo sapiens |
Year of Origin |
1984 |
References |
NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.
|